Spatial transcriptomic analysis of mouse parathyroid gland cells expressing an activating variant of Gcm2

  • Priyanka Bolel
  • , Jeremie Oliver Piña
  • , Fabio R. Faucz
  • , James R. Iben
  • , Wafa Abbas
  • , Smita Jha
  • , William F. Simonds
  • , Lee S. Weinstein
  • , Sunita K. Agarwal

Research output: Contribution to journalArticlepeer-review

Abstract

Glial cells missing 2 (GCM2) is an essential transcription factor for the development of parathyroid glands. Germline GCM2 variants that repress or enhance transcriptional activity predispose a subset of patients to hypoparathyroidism or hyperparathyroidism, respectively. A recurrent germline heterozygous activating missense variant of GCM2, p.Y394S has been identified in some patients with primary hyperparathyroidism. A genetically engineered knock-in mouse model of this variant corresponding to p.Y392S in the mouse Gcm2 gene (Gcm2+/Y392S) did not show obvious parathyroid tumors. However, in GCM2-binding site mediated luciferase reporter assays in HEK293 cells, the mouse and the human variant both exhibited enhanced transcriptional activity. Therefore, we assessed the effect of this variant on gene expression in vivo in parathyroid glands from Gcm2+/Y392S and WT mice. Using the 10x Genomics Visium platform, spatially resolved transcriptomic analysis was performed on formalin-fixed and paraffin-embedded (FFPE) tracheal tissue sections of Gcm2+/Y392S and WT mice to capture RNA from parathyroid glands together with other cell types in the tissue sections. Transcriptome sequence data analysis detected 8 different clusters in the tissue sections based on similarity of gene expression profiles. Cluster-1, which contained parathyroid gland cells expressing Pth and Gcm2, was further evaluated for transcripts that were differentially expressed more than 2-fold in Gcm2+/Y392S compared to WT. Increased transcript level of Lgals3 (galectin-3) was seen in Gcm2+/Y392S parathyroid gland cells which is among markers of parathyroid carcinoma. Galectin-3 protein was detected in available FFPE human parathyroid samples of patients with germline heterozygous activating GCM2 variants, p.Y394S (n = 4/10) or p.L379Q (n = 2/2). These results indicate a potential for growth and malignancy of parathyroid glands expressing GCM2 variants. The transcriptomic data of mouse parathyroid gland cells generated in this study can serve as a valuable resource for investigating genes and pathways in normal or abnormal parathyroid gland growth and physiology.

Original languageEnglish
Article numberziaf147
JournalJBMR Plus
Volume9
Issue number10
DOIs
StatePublished - 1 Oct 2025
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • expression
  • galectin-3
  • GCM2, gene
  • LGALS3
  • p.Y394S
  • parathyroid
  • primary hyperparathyroidism
  • spatial transcriptomics
  • Visium

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Orthopedics and Sports Medicine

Fingerprint

Dive into the research topics of 'Spatial transcriptomic analysis of mouse parathyroid gland cells expressing an activating variant of Gcm2'. Together they form a unique fingerprint.

Cite this